A comparison of clinical outcomes for diabetic and nondiabetic patients following directional atherectomy in the DEFINITIVE LE claudicant cohort

Journal of Endovascular Therapy

Volumn 22, Issue 5, 2015, Pages 701-711

  Garcia, Lawrence A ^a   Jaff, Michael R ^b   Rocha Singh, Krishna J ^c   Zeller, Thomas ^d   Bosarge, Christopher ^e   Kamat, Suraj ^f   McKinsey, James F ^g  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ST JOHN'S HOSPITAL   (United States)

^d UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^e Coastal Vascular and Interventional ^*  (United States)

^f Christus Spohn Hospital Alice   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Atherectomy; Claudication; Diabetes mellitus; Directional atherectomy; Infrapopliteal arteries; Patency; Peripheral artery disease; Popliteal artery; Superficial femoral artery; Target lesion revascularization

Indexed keywords

ADVERSE OUTCOME; AGED; ANKLE BRACHIAL INDEX; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DIRECTIONAL ATHERECTOMY; ECHOGRAPHY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; WALKING DIFFICULTY; ADVERSE EFFECTS; ATHERECTOMY; CLINICAL TRIAL; COMPARATIVE STUDY; CONVALESCENCE; DIABETIC ANGIOPATHIES; DISEASE FREE SURVIVAL; DUPLEX DOPPLER ULTRASONOGRAPHY; EUROPE; EXERCISE TOLERANCE; FEMORAL ARTERY; INTERMITTENT CLAUDICATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROCEDURES; RADIOGRAPHY; REGISTER; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; ATHERECTOMY; CONSTRICTION, PATHOLOGIC; DIABETIC ANGIOPATHIES; DISEASE-FREE SURVIVAL; EUROPE; EXERCISE TOLERANCE; FEMALE; FEMORAL ARTERY; HUMANS; INTERMITTENT CLAUDICATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RECOVERY OF FUNCTION; REGISTRIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; UNITED STATES; VASCULAR PATENCY;

EID: 84942094929     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602815599550     Document Type: Article

References (33)

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-321.
2. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract. 2012;98:524-525.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
4. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229-234.
5. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921-929.
6. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433-1437.
7. Bundo M, Munoz L, Perez C, et al. Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease. Ann Vasc Surg. 2010;24:985-993.
8. Palumbo PJ, O'Fallon WM, Osmundson PJ, et al. Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive? Arch Intern Med. 1991;151:717-721.
9. Leibson CL, Ransom JE, Olson W, et al. Peripheral arterial disease, diabetes, and mortality. Diabetes Care. 2004;27:2843-2849.
10. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738-743.
11. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96:44-49.
12. De Rubertis BG, Pierce M, Ryer EJ, et al. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg. 2008;47:101-108.
13. Sabeti S, Mlekusch W, Amighi J, et al. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12:6-12.
14. McKinsey JF, Zeller T, Rocha-Singh KJ, et al.; DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7:923-933.
15. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517-538.
16. McDermott MM, Liu K, Guralnik JM, et al. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg. 1998;28:1072-1081.
17. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
18. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
19. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10-19.
20. Micari A, Cioppa A, Vadala G, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331-338.
21. McKinsey JF, Goldstein L, Khan HU, et al. Novel treatment of patients with lower extremity ischemia: use of percutaneous atherectomy in 579 lesions. Ann Surg. 2008;248:519-528.
22. Blackwelder WC. "Proving the null hypothesis". in clinical trials. Control Clin Trials. 1982;3:345-353.
23. Brothers TE, Robison JG, Elliott BM. Diabetes mellitus is the major risk factor for African Americans who undergo peripheral bypass graft operation. J Vasc Surg. 1999;29:352-359.
24. Hakaim AG, Gordon JK, Scott TE. Early outcome of in situ femorotibial reconstruction among patients with diabetes alone versus diabetes and end-stage renal failure: analysis of 83 limbs. J Vasc Surg. 1998;27:1049-1054.
25. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
26. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49:1600-1606.
27. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110:1226-1230.
28. Abularrage CJ, Conrad MF, Hackney LA, et al. Long-term outcomes of diabetic patients undergoing endovascular infrainguinal interventions. J Vasc Surg. 2010;52:314-322.e1-4.
29. Fanelli F, Di Primo M, Boatta E, et al. Drug-eluting nitinol stent treatment of the superficial femoral artery and abovetheknee popliteal artery (the Zilver PTX single-arm clinical study): a comparison between diabetic and nondiabetic patients. Cardiovasc Intervent Radiol. 2013;36:1232-1240.
30. Fanelli F, Cannavale A, Corona M, et al. The "DEBELLUM".-lower limb multilevel treatment with drug eluting balloon-randomized trial: 1-year results. J Cardiovasc Surg (Torino). 2014;55:207-216.
31. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-S75.
32. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
33. Rocha-Singh K. Angiographic core laboratory assessments versus physician assessments: observations from the DEFINITIVE LE study. Presented at: The International Symposium on Endovascular Therapy; January 18-22, 2014; Miami, FL.